Recombinetics
Recombinetics, Inc. is a biotechnology company that specializes in the development and commercialization of gene editing technologies aimed at enhancing human health and improving animal agriculture. Founded in 2008 and based in Eagan, Minnesota, the company provides gene-edited pig models for medical clinics to facilitate testing in human cardiac therapeutics. Its proprietary TALENs technology allows for precise gene editing in large animals, supporting advancements in biomedical research, regenerative medicine, and improving animal welfare and productivity. By manipulating deoxyribonucleic acid (DNA) samples, Recombinetics enables the addition and activation of genes, thereby addressing health challenges and enhancing livestock productivity through precision breeding techniques.
Top Stages
1 past transactions
Makana Therapeutics
Acquisition in 2020
Makana Therapeutics is engaged in the development of genetically modified swine that exhibit reduced xenoantigen expression, facilitating the potential for human transplantation of cells, tissues, and organs from these animals. Founded in 2009 and based in Miami, Florida, the company aims to address the organ shortage crisis by commercializing a pipeline of transplantable materials, including those for the kidney, heart, lung, liver, blood, and pancreatic islets. By focusing on simplified genetics, optimized pig cloning techniques, and careful patient selection, Makana Therapeutics seeks to streamline product development and enhance the safety and efficacy of its transplantable offerings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.